SHP 647

Drug Profile

SHP 647

Alternative Names: MAdCAM MAb; PF-00547659; PF-547659; SHP647

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Pfizer
  • Class Antiulcers; Monoclonal antibodies
  • Mechanism of Action MADCAM1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Crohn's disease; Ulcerative colitis

Most Recent Events

  • 01 Jul 2016 Pfizer completes the phase II OPERA II trial in Crohn's disease in USA, Austria, Belgium, Bulgaria, Canada, France, Germany, Japan, South Korea, Netherlands, Norway, Poland, Serbia, South Africa, Slovakia, Spain and Sweden (NCT01298492)
  • 14 Jun 2016 PF 547659 licensed to Shire worldwide (9197926; Pfizer pipeline, August 2016)
  • 14 Jun 2016 Shire plans a phase III trials for SHP 647
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top